Search results
Ikervis is a medicine used to treat severe keratitis, an inflammation of the cornea (the transparent layer covering the front of the eye) in adult patients with dry eye disease. It is used when treatment with artificial tears (tear substitutes) is insufficient to improve the condition. Ikervis contains the active substance ciclosporin.
Active Ingredient: ciclosporin. Company: Santen UK Limited See contact details. ATC code: S01XA18. About Medicine. Prescription only medicine. Healthcare Professionals (SmPC) Patient Leaflet (PIL) This information is for use by healthcare professionals. Last updated on emc: 02 Mar 2022. Quick Links. Expand All. 1. Name of the medicinal product. 2.
The recommended dose is one drop of IKERVIS once daily to be applied to the affected eye(s) at bedtime. Response to treatment should be reassessed at least every 6 months. If a dose is missed, treatment should be continued on the next day as normal.
Product Overview. Introduction of Ikervis 1mg/ml Eye Drop Emulsion 0.3ml x30s. The majority of individuals do not have any negative side effects when using this medication. Headache, constipation, drowsiness or tiredness, and diarrhoea are the most prevalent adverse effects.
IKERVIS is a milky white eye drops emulsion. It is supplied in single-dose containers made of a low-density polyethylene (LDPE). Each single-dose container contains 0.3 mL eye drops, emulsion. The single-dose containers are wrapped in a sealed aluminium pouch. Pack sizes: 30 and 90 single-dose containers. Not all pack sizes may be marketed.
Ikervis is a medicine used to treat severe keratitis, an inflammation of the cornea (the transparent layer covering the front of the eye) in adult patients with dry eye disease. It is used when treatment with artificial tears (tear substitutes) is insufficient to improve the condition.
1. What IKERVIS is and what it is used for. 2. What you need to know before you use IKERVIS. 3. How to use IKERVIS. 4. Possible side effects. 5. How to store IKERVIS. 6. Contents of the pack and other information. This leaflet was last revised in 01/2022.
